Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00697385 · ClinicalTrials.gov registry record · NA

The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders

A NA study of Hemophilia and vonWillebrand Disease, sponsored by Mary M. Gooley Hemophilia Center.

Completed
Registry status
NA
Development phase
13
Enrollment target
1
Study location

NCT00697385 is a NA study of Hemophilia and vonWillebrand Disease that has completed, run by Mary M. Gooley Hemophilia Center. The registered enrollment target is 13 participants, below the 409-participant average among 9 other Hemophilia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00697385, a NA study of Hemophilia and vonWillebrand Disease, has completed, sponsored by Mary M. Gooley Hemophilia Center.

COMPLETED
Registry status
NA
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

The high percentage of failure using available non-surgical options to treat menorrhagia in women with bleeding disorders shows a continuing need for innovative treatments. This has led to development of this protocol in order to make available tranexamic acid as a potentially effective menorrhagia therapy option in women with an underlying bleeding disorder. We anticipate that Tranexamic Acid may be a beneficial choice for controlling menorrhagia in bleeding disorder patients.

Interventions

  • DRUG Cyclokapron

Study Locations (1)

New York

  • Mary M. Gooley Hemophilia Center - Rochester

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2003-04
Est. Completion 2008-06
Phase NA

Sponsor

Mary M. Gooley Hemophilia Center

1 total trials

What the Registry Record Tells You About NCT00697385

The ClinicalTrials.gov registry entry for NCT00697385 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 409-participant average among 9 other Hemophilia trials with a reported enrollment target (97% lower). The listed sponsor is Mary M. Gooley Hemophilia Center, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hemophilia appearing as the primary indexed condition, and to 1 intervention - of which Cyclokapron is the first listed.

NCT00697385 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00697385 about?

NCT00697385 is a clinical study titled "The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders". The high percentage of failure using available non-surgical options to treat menorrhagia in women with bleeding disorders shows a continuing need for innovative treatments. This has led to development of this protocol in order to make available tranexamic acid as a potentially effective menorrhagia ...

What is the current status of trial NCT00697385?

This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2003-04. Estimated completion is 2008-06.

What conditions does trial NCT00697385 study?

This clinical trial studies the following conditions: Hemophilia, vonWillebrand Disease, Platelet Coagulation Disorders.

What interventions are being tested in trial NCT00697385?

The interventions under investigation include: Cyclokapron (DRUG).

Who is sponsoring clinical trial NCT00697385?

This trial is sponsored by Mary M. Gooley Hemophilia Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00697385 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemophilia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.